@article{3105362,
    title = "Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy",
    author = "Terpos, E. and Kostopoulos, I.V. and Kastritis, E. and Ntanasis-Stathopoulos, I. and Migkou, M. and Rousakis, P. and Argyriou, A.T. and Kanellias, N. and Fotiou, D. and Eleutherakis-Papaiakovou, E. and Gavriatopoulou, M. and Ziogas, D.C. and Papanota, A.-M. and Spyropoulou-Vlachou, M. and Trougakos, I.P. and Tsitsilonis, O.E. and Paiva, B. and Dimopoulos, M.A.",
    journal = "Hemasphere",
    year = "2019",
    volume = "3",
    number = "6",
    publisher = "Ovid Technologies (Wolters Kluwer Health)",
    doi = "10.1097/HS9.0000000000000300",
    keywords = "bortezomib;  daratumumab;  immunoglobulin A;  immunoglobulin D;  immunoglobulin G;  melphalan, adult;  aged;  Article;  B lymphocyte subpopulation;  bone marrow biopsy;  controlled study;  disease association;  drug megadose;  erythroblast;  female;  flow cytometry;  follow up;  high throughput sequencing;  human;  maintenance therapy;  major clinical study;  male;  middle aged;  minimal residual disease;  multiple myeloma;  phenotype;  priority journal;  prospective study;  treatment duration;  tumor diagnosis;  tumor volume",
    abstract = "Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10-5; 17% at 10-6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts' and tumor-associated monocytes/macrophages' predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10-6. © 2019 the Author(s). Published by Wolters Kluwer Health, Inc."
}